<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02787291</url>
  </required_header>
  <id_info>
    <org_study_id>SJM-CIP-CRD768</org_study_id>
    <nct_id>NCT02787291</nct_id>
  </id_info>
  <brief_title>A Clinical Evaluation of the Durata or Optisure High Voltage Leads and Ellipse VR ICD Undergoing MRI, an IDE Study</brief_title>
  <acronym>MRI Ready IDE</acronym>
  <official_title>A Clinical Evaluation of the Durata or Optisure High Voltage Leads and Ellipse VR ICD Undergoing Magnetic Resonance Imaging, an Investigational Device Exemption (IDE) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate safety and efficacy of the Durata or Optisure high voltage lead and Ellipse VR&#xD;
      ICD in an MRI environment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The intent of this IDE study is to evaluate the safety and efficacy of the Durata or Optisure&#xD;
      lead and Ellipse VR ICD that have undergone an MRI scan. The patient population under study&#xD;
      includes patients indicated for or who have been implanted with a Durata or Optisure lead and&#xD;
      an Ellipse VR ICD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Actual">April 11, 2018</completion_date>
  <primary_completion_date type="Actual">January 12, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With MRI Scan Related Complications</measure>
    <time_frame>MRI scan to 1 month post MRI scan</time_frame>
    <description>The primary safety endpoint is the number of participants that had an Ellipse ICD and/or a Durata or Optisure lead complication from the day the MRI scan occurred to the 1-month visit. A complication is defined as a serious adverse device effect that requires an invasive intervention or leads to death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Ventricular Capture Threshold ≤ to 0.5V</measure>
    <time_frame>pre-MRI scan to 1 month post MRI scan</time_frame>
    <description>Percentage of participants of Durata or Optisure (RV) leads implanted with the Ellipse VR ICD with capture threshold increase of ≤ 0.5V at 0.5ms from pre-MRI scan to 1 month post-MRI scan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Ventricular Sensing Amplitude Decrease of ≤ 50% From Pre-MRI Scan to 1 Month Post MRI Scan</measure>
    <time_frame>pre-MRI scan to 1 month post MRI scan</time_frame>
    <description>Percentage of Participants with Durata or Optisure RV leads implanted with the Ellipse VR ICD with sensing amplitude decrease of ≤ 50% from pre-MRI scan to 1 month post MRI scan.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">227</enrollment>
  <condition>Implantable Defibrillator User</condition>
  <arm_group>
    <arm_group_label>Ellipse VR ICD and Durata/Optisure lead</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Pts with Ellipse VR ICD and Durata or Optisure RV lead implanted for at least 60 days will receive a non-diagnostic MRI scan of head and chest region</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ellipse VR ICD and Durata/Optisure lead</intervention_name>
    <description>Non-diagnostic MRI Scan sequence of head and chest</description>
    <arm_group_label>Ellipse VR ICD and Durata/Optisure lead</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are implanted with the Durata or Optisure lead for at least 60 days (can include&#xD;
             patients with Durata or Optisure lead for &gt; 60 days OR patients with a new Ellipse VR&#xD;
             ICD and/or Durata/Optisure lead implanted for at least 60 days&#xD;
&#xD;
          -  Are implanted with an Ellipse VR ICD pectorally&#xD;
&#xD;
          -  Be willing to undergo an elective MRI scan without sedation NOTE: Antianxiety agents&#xD;
             (e.g. minor tranquilizers, etc.) may be used as long as the patient can communicate&#xD;
             with site personnel during the MRI scan&#xD;
&#xD;
          -  Capture threshold is stable &lt; 2.5V @ 0.5ms&#xD;
&#xD;
          -  Ventricular sensing is measurable (patient has underlying rhythm &gt; 30bpm) and the&#xD;
             sensing amplitude is &gt; 4mV&#xD;
&#xD;
          -  Be able to provide informed consent for study participation (legal guardian or legally&#xD;
             authorized representative is NOT acceptable)&#xD;
&#xD;
          -  Be willing and able to comply with the prescribed follow-up tests and procedures&#xD;
&#xD;
          -  Are not contraindicated for an MRI scan (per the MRI Screening Form)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a competitor's MRI compatible endocardial lead implanted or capped&#xD;
&#xD;
          -  Have another existing active implanted medical device, e.g., neurostimulator, infusion&#xD;
             pump, etc., that has MR labeling that will not allow the MRI scans per this protocol&#xD;
             to be completed.&#xD;
&#xD;
          -  Have a lead revision of the Durata/Optisure lead occur &lt; 60 days of the baseline visit&#xD;
&#xD;
          -  Have other non-MRI compatible device or material implanted NOTE: MRI compatible knee&#xD;
             replacements, hip replacements, stents, etc. may be included as long as the labeling&#xD;
             of these devices allow MRI scans conducted per this protocol NOTE: MRI compatible&#xD;
             mechanical, prosthetic, and bioprosthetic heart valves may be included as long as the&#xD;
             labeling of these devices allow for MRI scans conducted per this protocol NOTE:&#xD;
             Non-removable dental implants may be included&#xD;
&#xD;
          -  Have a lead extender, adaptor, or capped/abandoned lead&#xD;
&#xD;
          -  Enrolled or intend to participate in a clinical drug and/or device study&#xD;
             (investigational device, investigational drug, new indication for a device or drug or&#xD;
             additional testing beyond standard of care procedures), which could confound the&#xD;
             results of this trial as determined by SJM.&#xD;
&#xD;
          -  Pregnant or planning to become pregnant during the duration of the subject's&#xD;
             participation in the study&#xD;
&#xD;
          -  Have a life expectancy of less than 12 months due to any condition&#xD;
&#xD;
          -  Patients with exclusion criteria required by local law (e.g., age)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saman Nazarian, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>John C. Lincoln North Mountain Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Cardiology</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Health</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Athens Regional Medical Center</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Redmond Regional Medical Center</name>
      <address>
        <city>Rome</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prairie Education and Research Cooperative</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkview Research Center</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Consultants</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sparrow Clinical Research Institute</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Hospital</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson Heart Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samaritan Heart &amp; Vascular Institute</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Consultants in Cardiovascular Diseases</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health System</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Donald Guthrie Foundation for Education and Research</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist University Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Thomas Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor All Saints Medical Center at Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University Hospital</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Medical Group</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiac Rhythm Specialists, S.C.</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Premienienia Panskiego</name>
      <address>
        <city>Poznan</city>
        <state>Silesia</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Heart of Poland SA</name>
      <address>
        <city>Tychy</city>
        <state>Silesia</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carint Scanmed Sp. z.o.o.</name>
      <address>
        <city>Krakow</city>
        <state>Voivode</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <state>Castellon</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Clydebank</city>
        <state>West Dunbartonshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 20, 2016</study_first_submitted>
  <study_first_submitted_qc>May 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2016</study_first_posted>
  <results_first_submitted>August 16, 2019</results_first_submitted>
  <results_first_submitted_qc>August 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 3, 2020</results_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 17, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT02787291/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ellipse VR ICD and Durata/Optisure Lead</title>
          <description>Pts with Ellipse VR ICD and Durata or Optisure RV lead implanted for at least 60 days will receive a non-diagnostic MRI scan of head and chest region&#xD;
Ellipse VR ICD and Durata/Optisure lead: Non-diagnostic MRI Scan sequence of head and chest</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="227"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="227"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ellipse VR ICD and Durata/Optisure Lead</title>
          <description>Pts with Ellipse VR ICD and Durata or Optisure RV lead implanted for at least 60 days will receive a non-diagnostic MRI scan of head and chest region&#xD;
Ellipse VR ICD and Durata/Optisure lead: Non-diagnostic MRI Scan sequence of head and chest</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="227"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.9" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With MRI Scan Related Complications</title>
        <description>The primary safety endpoint is the number of participants that had an Ellipse ICD and/or a Durata or Optisure lead complication from the day the MRI scan occurred to the 1-month visit. A complication is defined as a serious adverse device effect that requires an invasive intervention or leads to death.</description>
        <time_frame>MRI scan to 1 month post MRI scan</time_frame>
        <population>Of 227 subjects enrolled, 209 subjects completed the pre-MRI scan visit. Of the 209 subjects, 4 subjects did not have eligible study leads, 3 withdrew before 1-month post MRI scan visit and 4 missed 1-month post MRI scan visit. Therefore, 198 subjects who completed 1-month post MRI scan were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ellipse VR ICD and Durata/Optisure Lead</title>
            <description>Pts with Ellipse VR ICD and Durata or Optisure RV lead implanted for at least 60 days will receive a non-diagnostic MRI scan of head and chest region&#xD;
Ellipse VR ICD and Durata/Optisure lead: Non-diagnostic MRI Scan sequence of head and chest</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With MRI Scan Related Complications</title>
          <description>The primary safety endpoint is the number of participants that had an Ellipse ICD and/or a Durata or Optisure lead complication from the day the MRI scan occurred to the 1-month visit. A complication is defined as a serious adverse device effect that requires an invasive intervention or leads to death.</description>
          <population>Of 227 subjects enrolled, 209 subjects completed the pre-MRI scan visit. Of the 209 subjects, 4 subjects did not have eligible study leads, 3 withdrew before 1-month post MRI scan visit and 4 missed 1-month post MRI scan visit. Therefore, 198 subjects who completed 1-month post MRI scan were included in the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Ventricular Capture Threshold ≤ to 0.5V</title>
        <description>Percentage of participants of Durata or Optisure (RV) leads implanted with the Ellipse VR ICD with capture threshold increase of ≤ 0.5V at 0.5ms from pre-MRI scan to 1 month post-MRI scan.</description>
        <time_frame>pre-MRI scan to 1 month post MRI scan</time_frame>
        <population>Of 227 subjects enrolled, 209 subjects completed the pre-MRI scan visit. Of the 209 subjects, 4 did not have eligible study leads, 13 were missing capture threshold measurements, 3 withdrew before the 1-month post MRI scan visit and 2 missed the 1-month post MRI scan visit. Therefore, 187 subjects were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ellipse VR ICD and Durata/Optisure Lead</title>
            <description>Pts with Ellipse VR ICD and Durata or Optisure RV lead implanted for at least 60 days will receive a non-diagnostic MRI scan of head and chest region&#xD;
Ellipse VR ICD and Durata/Optisure lead: Non-diagnostic MRI Scan sequence of head and chest</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Ventricular Capture Threshold ≤ to 0.5V</title>
          <description>Percentage of participants of Durata or Optisure (RV) leads implanted with the Ellipse VR ICD with capture threshold increase of ≤ 0.5V at 0.5ms from pre-MRI scan to 1 month post-MRI scan.</description>
          <population>Of 227 subjects enrolled, 209 subjects completed the pre-MRI scan visit. Of the 209 subjects, 4 did not have eligible study leads, 13 were missing capture threshold measurements, 3 withdrew before the 1-month post MRI scan visit and 2 missed the 1-month post MRI scan visit. Therefore, 187 subjects were included in the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Ventricular Sensing Amplitude Decrease of ≤ 50% From Pre-MRI Scan to 1 Month Post MRI Scan</title>
        <description>Percentage of Participants with Durata or Optisure RV leads implanted with the Ellipse VR ICD with sensing amplitude decrease of ≤ 50% from pre-MRI scan to 1 month post MRI scan.</description>
        <time_frame>pre-MRI scan to 1 month post MRI scan</time_frame>
        <population>Of 227 subjects enrolled, 209 subjects completed the pre-MRI scan visit. Of the 209 subjects, 4 subjects did not have eligible study leads, 3 withdrew before 1-month post MRI scan visit and 4 missed 1-month post MRI scan visit. Therefore, 198 subjects who completed 1-month post MRI scan were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ellipse VR ICD and Durata/Optisure Lead</title>
            <description>Pts with Ellipse VR ICD and Durata or Optisure RV lead implanted for at least 60 days will receive a non-diagnostic MRI scan of head and chest region&#xD;
Ellipse VR ICD and Durata/Optisure lead: Non-diagnostic MRI Scan sequence of head and chest</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Ventricular Sensing Amplitude Decrease of ≤ 50% From Pre-MRI Scan to 1 Month Post MRI Scan</title>
          <description>Percentage of Participants with Durata or Optisure RV leads implanted with the Ellipse VR ICD with sensing amplitude decrease of ≤ 50% from pre-MRI scan to 1 month post MRI scan.</description>
          <population>Of 227 subjects enrolled, 209 subjects completed the pre-MRI scan visit. Of the 209 subjects, 4 subjects did not have eligible study leads, 3 withdrew before 1-month post MRI scan visit and 4 missed 1-month post MRI scan visit. Therefore, 198 subjects who completed 1-month post MRI scan were included in the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month post MRI scan</time_frame>
      <desc>Protocol defined ADE (Adverse Device Effects), SADEs (Serious Adverse Device Effects), UADE (Unanticipated Adverse Device Effects), and USADEs (Unanticipated Serious Adverse Device Effects) were collected in this trial and were adjudicated by a Clinical Events Committee</desc>
      <group_list>
        <group group_id="E1">
          <title>Ellipse VR ICD and Durata/Optisure Lead</title>
          <description>Pts with Ellipse VR ICD and Durata or Optisure RV lead implanted for at least 60 days will receive a non-diagnostic MRI scan of head and chest region&#xD;
Ellipse VR ICD and Durata/Optisure lead: Non-diagnostic MRI Scan sequence of head and chest</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Adam Cline- Clinical Scientist</name_or_title>
      <organization>Abbott CAHF CRM</organization>
      <phone>818-493-2025</phone>
      <email>adam.cline@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

